Posted by Michael Wonder on 31 May 2022
Timber Pharmaceuticals receives FDA breakthrough therapy designation for TMB-001 for the treatment of congenital ichthyosis
31 May 2022 - Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial.
Timber Pharmaceuticals today announced that the U.S. FDA has granted breakthrough therapy designation to TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG delivery system, for the treatment of congenital ichthyosis.
